| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | IDH; IDP; IDHM; IDPM; ICD-M; D2HGA2; mNADP-IDH |
| WB Predicted band size | 51 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human IDH2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与IDH2抗体相关的文献摘要，供参考：
1. **《Antibody-based detection of IDH2 R172K mutations in human gliomas》**
- **作者**：Capper D., et al.
- **摘要**：研究开发了一种特异性识别IDH2 R172K突变的单克隆抗体(克隆16H6)，通过免疫组化(IHC)在胶质瘤组织中检测突变蛋白表达，验证了其与DNA测序结果的高度一致性，为临床病理诊断提供了快速检测工具。
2. **《Mutant IDH2-specific immunohistochemistry for the detection of acute myeloid leukemia》**
- **作者**：Fathi A.T., et al.
- **摘要**：验证了一种抗IDH2 R140Q突变蛋白的抗体在急性髓系白血病(AML)骨髓样本中的应用。该抗体通过IHC可有效区分突变型与野生型IDH2.辅助AML分子分型及预后评估。
3. **《A novel IDH2 antibody highlights the oncogenic role of cytoplasmic IDH2 mutations in cancer metabolism》**
- **作者**：Yen K.E., et al.
- **摘要**：报道了一种新型兔源多克隆抗体，特异性识别IDH2 R172位点突变体，用于Western blot和免疫荧光检测。研究发现突变的IDH2在细胞质中异常累积，导致2-羟基戊二酸(2-HG)过量生成，促进肿瘤代谢重编程。
---
以上文献均聚焦于IDH2突变特异性抗体的开发与应用，涉及胶质瘤、白血病等疾病的诊断及机制研究。如需全文链接或补充其他文献，可进一步说明。
The IDH2 antibody is a critical tool in cancer research and diagnostics, targeting isocitrate dehydrogenase 2 (IDH2), a metabolic enzyme located in mitochondria. IDH2 plays a role in the citric acid cycle, catalyzing the conversion of isocitrate to α-ketoglutarate (α-KG). Mutations in the IDH2 gene, particularly at residue R172. are recurrent in cancers like gliomas, acute myeloid leukemia (AML), and chondrosarcomas. These mutations confer neomorphic activity, enabling IDH2 to produce the oncometabolite D-2-hydroxyglutarate (2-HG), which disrupts cellular differentiation and epigenetic regulation.
IDH2 antibodies are designed to detect wild-type or mutant IDH2 proteins in assays such as immunohistochemistry (IHC), Western blotting, or flow cytometry. They are essential for identifying IDH2 mutation status, a biomarker with diagnostic, prognostic, and therapeutic implications. For instance, IDH2-mutated AML is associated with better outcomes in specific treatments. Additionally, mutant IDH2 antibodies aid in research to elucidate mechanisms of tumorigenesis and evaluate targeted therapies, such as IDH2 inhibitors (e.g., enasidenib).
Clinically, these antibodies support molecular subtyping of tumors, guiding personalized treatment strategies. However, challenges remain in ensuring antibody specificity to distinguish IDH2 mutants from wild-type isoforms or related proteins like IDH1. Validation in diverse sample types (e.g., formalin-fixed tissues) is critical for diagnostic accuracy. Overall, IDH2 antibodies are pivotal in advancing precision oncology and understanding metabolic dysregulation in cancer.
×
